Interestingly, BAY-1895344, a highly potent and selective ATRi with strong anti-proliferative effects in various cancer cell lines and xenograft models, was recently studied in a human Phase I trial, reporting that it was well tolerated and exhibited anti-tumor activity in refractory solid tumors, and non-Hodgkin’s and mantle cell lymphomas with ATM deficiencies [206,207]. Here, ATM is linked to neoplasm.